Clinical Policy Title: Gene expression profile testing for breast cancer
|
|
- Randolf Booth
- 7 years ago
- Views:
Transcription
1 Clinical Policy Title: Gene expression profile testing for breast cancer Clinical Policy Number: Effective Date: December 1, 2013 Initial Review Date: July 17, 2013 Most Recent Review Date: April 27, 2016 Next Review Date: April 2017 Related policies: Policy contains: Gene expression profile/assay/test. Breast cancer. Oncotype DX. MammaPrint. OpenArray RealTime PCR CP# CP# Genetic testing for breast and ovarian cancer Breast cancer screening in women ABOUT THIS POLICY: Select Health of South Carolina has developed clinical policies to assist with making coverage determinations. Select Health of South Carolina s clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of medically necessary, and the specific facts of the particular situation are considered by Select Health of South Carolina when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. Select Health of South Carolina s clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. Select Health of South Carolina s clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, Select Health of South Carolina will update its clinical policies as necessary. Select Health of South Carolina s clinical policies are not guarantees of payment. Coverage policy Select Health of South Carolina considers the use of 21-gene expression profile testing (i.e., Oncotype DX ) in early-stage breast cancer to be clinically proven and, therefore, medically necessary where the following criteria are met: Breast cancer is nonmetastatic, or with 1 3 involved ipsilateral axillary lymph nodes; AND Breast tumor is estrogen receptor positive; AND Breast tumor is HER-2 receptor negative or breast tumor is HER2 receptor positive and less than 1 cm in diameter; AND Adjuvant chemotherapy is not contraindicated due to any other factor (e.g., advanced age and/or significant co-morbidities); AND Member and physician (prior to testing) have discussed the potential results of the test and agree to use the results to guide therapy. 1
2 Limitations: All other uses of gene expression testing for breast cancer are not medically necessary. Note: The following CPT/HCPCS codes are not listed in the South Carolina Medicaid fee schedule: Oncology (breast), mrna, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin embedded tissue, algorithm reported as recurrence score (Oncotype Dx) Alternative Covered Services: None. Background Breast cancer is the most common cancer among women worldwide and the leading cause of premature mortality among women in the United States. In 2015, the American Cancer Society estimated that 231,840 women were diagnosed with breast cancer and 40,290 women died in the United States of the disease. Genetic testing or gene expression testing includes a variety of laboratory tests (analysis of deoxyribonucleic acid [DNA], ribonucleic acid [RNA], genes or gene products) for the purposes of: Diagnosing breast cancer and other diseases. Assisting in treatment decisions (e.g., adding adjuvant chemotherapy to the radical surgical treatment of breast cancer). Predicting future breast disease (e.g., cancer in the contralateral breast). Identifying carriers of disease to prevent generational occurrence of breast cancer. The results of a contemporary large multicenter, multinational trial have given support to the validity of molecular genetic testing for breast cancer. Although only one genetic assay, the Oncotype DX 21-gene expression test, made by Genomic Health Inc., was endorsed by the results of the TAILORx study released in November 2015, it is likely that others will emerge in the future and that the management of cancers other than breast cancer will eventually be impacted. The MammaPrint test, made by Agendia, is a genomic test that analyzes the activity of certain genes in early-stage breast cancer. The European Organization for Research and Treatment of Cancer is currently studying MammaPrint as part of its microarray in node-negative and 1 3 positive lymph node disease may avoid chemotherapy (MINDACT) project, which is a prospective randomized study comparing the 70-gene expression profile with the common clinical-pathological criteria in selecting patients with 0 3 positive nodes for adjuvant chemotherapy in breast cancer. Early results suggest the MammaPrint test may eventually be widely used to help make treatment decisions based on the risk of recurrence of breast cancer within 10 years after diagnosis. OpenArray Real-Time polymerase chain reaction (PCR) is a new approach to nucleic acid detection and quantification, which is a different method of absolute quantification and rare allele detection relative to conventional PCR. It works by partitioning a sample into many individual real-time PCR reactions; some portion of these reactions contain the target molecule (positive), while others do not (negative). Following PCR analysis, the fraction negative answers generates an absolute answer for the exact number of target molecules in the sample, without reference to standards or endogenous controls. 2
3 Searches Select Health of South Carolina searched PubMed and the databases of: UK National Health Services Center for Reviews and Dissemination. Agency for Healthcare Research and Quality s National Guideline Clearinghouse and other evidence-based practice centers. The Centers for Medicare & Medicaid Services (CMS). We conducted searches on March 1, Searched terms were: " breast cancer (MeSH)," and "gene expression test (MeSH)." We included: Systematic reviews, which pool results from multiple studies to achieve larger sample sizes and greater precision of effect estimation than in smaller primary studies. Systematic reviews use predetermined transparent methods to minimize bias, effectively treating the review as a scientific endeavor, and are thus rated highest in evidence-grading hierarchies. Guidelines based on systematic reviews. Economic analyses, such as cost-effectiveness, and benefit or utility studies (but not simple cost studies), reporting both costs and outcomes sometimes referred to as efficiency studies which also rank near the top of evidence hierarchies. Findings The American Society of Clinical Oncology (ASCO) has promulgated clinical practice guidelines to provide recommendations on the appropriate use of breast tumor biomarker assays for guiding decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer (Harris, 2016). A literature search from 2006 through 2014 identified 50 relevant studies with medical evidence of clinical utility for the Oncotype DX biomarker assay. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP 2015) working group found that the available medical evidence supports the clinical validity of Oncotype DX in predicting risk of distant metastases in women with hormone receptor-positive (HR+), early-stage breast cancer that is either node-negative or node-positive. However, no direct evidence was found that use of Oncotype DX tumor gene expression profiling to guide treatment decisions improves clinical outcomes in women with early breast cancer. Finally, the group noted that there is indirect evidence, from retrospective studies on archived tissue samples from randomized controlled trials (RCTs), that the Oncotype DX test can predict benefit from chemotherapy. They also affirmed that Oncotype DX testing has been reported, based on economic modeling studies, to be cost-effective in several different health care systems and to save costs in the U.S. health care setting; however, these studies were based on assumptions regarding the clinical utility of the test that require confirmation by clinical trial results. Dreyfus (2015) found the 21-gene assay Oncotype DX assay may be used to estimate the risk of recurrence and to predict the benefit of adjuvant chemotherapy at an early stage of endocrine responsive breast cancers, without human epidermal growth factor receptor 2 (HER-2) overexpression or amplification. The Oncotype DX test correlates positively with recurrence score (RS), classifying patients into three groups of low, intermediate or high risk. Between August 2013, and May 2015, the Oncotype DX assay was applied to patients with indication for adjuvant 3
4 chemotherapy for HR+ and HER-2 negative cancers. Twenty-six (66.7 percent) of 39 women were identified as having unlikely material indication for chemotherapy. The economy obtained through the use of the test was estimated at 173,000 euros. The authors concluded using Oncotype DX reduced the indications for adjuvant chemotherapy, and generated significant beneficial medical and economic impact. An analysis of a subset of results of the TAILORx trial, published in the New England Journal of Medicine (Sparano, 2015), showed that a majority of women with early-stage breast cancer who receive a low-risk score from a 21-gene expression assay (Oncotype DX test) remain disease-free after five years of hormonal therapy alone, without added chemotherapy. TAILORx enrolled 10,273 patients across 1,182 sites in six countries, including the United States and Canada. The clinical trial enrolled women ages with estrogen receptor (ER) positive, HER-2/neu negative, nodenegative invasive breast cancers either >1cm or cm in size with intermediate- to highhistologic grade. Every patient in the trial was tested with the assay, which divides women based on an analysis of the expression of 21 genes, into one of three risk categories: low, intermediate and high. In the trial, women with an Oncotype DX RS of 10 received hormonal therapy alone; women with an RS >25 were treated with hormonal therapy plus chemotherapy; while women with a midrange RS from the primary study group were randomized to receive hormonal therapy with or without chemotherapy. The RS 10 women (n=1,629) demonstrated an impressive rate of invasive disease-free survival of 93.8 percent, and freedom from recurrence of breast cancer at a distant site was 99.3percent. Freedom from recurrence was 98.7percent and overall survival was 98 percent in this cohort. Multivariate analysis did not reveal an effect of age, tumor size or type of surgery on rate of recurrence or survival. Histologic grade showed an association with risk of recurrence. The study provides prospective validation for the use of OncotypeDX RS to spare patients from chemotherapy who would otherwise be recommended to receive it. The study was sponsored by the National Cancer Institute (NCI). On the downside, only 16 percent of women tested with Oncotype DX fell into the low RS group; and although these results (at five years of follow up) are impressive, late recurrence of invasive breast cancer after five years typically accounts for nearly half of all distant recurrences from breast cancer. The National Institute for Health and Clinical Excellence (NICE) of the United Kingdom published provisional guidelines in 2013 and endorsed the use of the 21-gene expression profile assay in the management of early breast cancer. Oncotype DX was recommended for estrogen receptor-positive lymph node negative and HER-2 negative breast cancer to guide chemotherapy decisions. 4
5 Summary of clinical evidence: Citation Harris (2016) EGAPP (2015) Content, Methods, Recommendations ASCO recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer. A literature search and prospectively defined study selection sought systematic reviews, meta-analyses, RCTs, prospective and retrospective studies, and prospective comparative observational studies published from 2006 through Outcomes of interest included overall survival and disease-free or recurrence-free survival. Expert panel members used informal consensus to develop evidence-based guideline recommendations. The literature search identified 50 relevant studies. One RCT and 18 retrospective studies were found to have evaluated the clinical utility, as defined by the guideline, of specific biomarkers for guiding decisions on the need for adjuvant systemic therapy. No studies that met guideline criteria for clinical utility were found to guide choice of specific treatments or regimens. In addition to estrogen and progesterone receptors and HER-2, the panel found sufficient evidence of clinical utility for the biomarker assays Oncotype DX, EndoPredict, PAM50, Breast Cancer Index, and urokinase plasminogen activator and plasminogen activator inhibitor type 1 in specific subgroups of breast cancer. No biomarker except for estrogen receptor, progesterone receptor and HER-2 was found to guide choices of specific treatment regimens. Treatment decisions should also consider disease stage, comorbidities and patient preferences. In women with early-stage invasive breast cancer, gene expression profiling is increasingly being used as an aid to estimate the likely benefit from chemotherapy treatment. EGAPP found adequate evidence for clinical validity of Oncotype DX in the population of women with lymph node-positive disease, using evidence from recent systematic reviews and other sources. EGAPP found that new evidence supports the clinical validity of Oncotype DX in predicting risk of distant metastases in women with hormone receptor-positive, early-stage breast cancer that is either node-negative or node-positive. No direct evidence was found that use of Oncotype DX tumor gene expression profiling to guide treatment decisions improves clinical outcomes in women with early breast cancer. There is indirect evidence, from prospective retrospective studies on archived tissue samples from RCTs, that the Oncotype DX test can predict benefit from chemotherapy. Although Oncotype DX testing has been reported, on the basis of economic modeling studies, to be cost-effective in several different health-care systems and to save costs in the United States health-care setting, studies were based on assumptions regarding the clinical utility of the test that require confirmation by clinical trial results. 5
6 Dreyfus (2015) Sparano (2015) The 21-gene assay (Oncotype DX ) test corresponds to an RS, classifying patients into three groups (low, intermediate or high risk). Thirty-nine patients had the test, 26 (66.7%) of them demonstrating diminished indication regarding chemotherapy. The economy obtained through the use of the test was estimated around 173,000 euros. The RS provided an additional decision value compared to other common decision criteria. Use of Oncotype DX reduced the need of adjuvant chemotherapy and the medical and economic impact could be significant. RCT inclusive of 10,253 patients diagnosed with invasive breast cancer included a cohort of 1,626 women (15.9%) who had a recurrence score of 0 10 on 21-gene expression assay (i.e., OncotypeDX ). Patients with hormone-receptor positive, HER2-negative, axillary node negative breast cancers that had a favorable gene-expression profile had very low rates of recurrence at five years with endocrine therapy alone. NICE (2013) Cosler (2009) Guidelines for use of gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in early breast cancer management: Oncotype DX recommended for estrogen receptor-positive lymph node negative and HER-2 negative breast cancer to guide chemotherapy decisions. Prospective study of costs and outcomes of using 21-gene expression profile data to guide treatment decisions for women with early stage breast cancer. Gene expression profiling was associated with a survival gain of 2.2 years. Bias was implied as the study was supported by test manufacturer and incompletely reported. Marchionni (2008) Retrospective study focused on Oncotype DX and MammaPrint gene expression profiling tests on breast cancer outcomes. Found no direct evidence for impact on outcomes. Glossary Estrogen receptor (ER) A group of intracellular proteins used to predict prognosis and select treatment in breast cancer patients. The precise mechanisms of action are incompletely understood but their role in anticipating prognosis is well documented. Genetic testing (also known as gene expression assay and gene expression profiling) A type of test used to determine the presence or absence of a specific gene or set of genes to help diagnose a disease, screen for specific health conditions and for other purposes. Hormone receptor (HR) Breast cancer that is responsive to hormones (implying that hormone receptors are present on the cells of the cancer) is referred to as HR-positive or HR+; thus, the tumor can be treated with therapies that block the hormones from the cancer cells. 6
7 Human epidermal growth factor 2 receptor (HER-2) Her-2 is a protein coded by the ERBB2 gene. Amplification or overexpression of this gene has been shown to play a role in the pathogenesis and progression of aggressive types of breast cancer; however, there are treatments that specifically target the Her-2 receptor and offer effective treatment of the cancer. References Professional associations/other: Agency for Healthcare Research and Quality (AHRQ). Impact of gene expression profiling tests on breast cancer outcomes. Evidence report/technology assessment Number 160. AHRQ Publication No. 08-E002. January Hayes Inc., Hayes Medical Technology Brief. MammaPrint (Agendia BV) Genetic assay for breast cancer. Lansdale, Pa. Hayes Inc.; May, Harris LN, Ismaila N, McShane LM, et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016; 8. pii: JCO National Institute for Health and Clinical Excellence (NICE) Early and locally advanced breast cancer: diagnosis and treatment. London (UK): National Institute for Health and Clinical Excellence (NICE). Clinical guideline no National Institute for Health and Clinical Excellence (NICE). Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in early breast cancer management MammaPrint, Oncotype Dx, IHC4, and Mammostrat. Diagnostics consultation document Peer-reviewed references: Cosler LE, Lyman GH. Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. Cancer Investigation.2009;27(10): de Groot S, Charehbili A, van Laarhoven H, et al. Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG ). Breast Cancer Res. 2016; 18: 3. Dreyfus C, Ballester M, Gligorov J, et al. Impact of the 21-gene assay in decision-making during multidisciplinary breast meeting: A French experience. Gynecol Obstet Fertil. 2015;43(12): Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer? Genet Med. 2015; 17. Ingoldsby H, Webber M, Wall D, Scarrott C, Newell J, Callagy G. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis. Breast. 2013;10(1016):
8 McVeigh TP, Hughes LM, et al. The impact of Oncotype Dx testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral center. European journal of Cancer.2014;50(16) Mislick K, Schonfeld W, et al. Cost-effectiveness of Mammostrat compared with Oncotype DX to inform the management of breast cancer. Clinico-economics and Outcomes Research. 2014;6: Sparano J, Gray R, Makower D, et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2015; 373: Clinical trials: Searched clinicaltrials.gov on March 7, 2016, using terms gene expression profile testing for breast cancer Open Studies. Twenty-nine studies were found, four were relevant. ECOG-ACRIN Cancer Research Group and National Cancer Institute (NCI). MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ. ClinicalTrials.gov website. Published January, Updated September Accessed March 7, Case Comprehensive Cancer Center. Assessment of Candidate Protein Expression in Breast Cancer Specimens. ClinicalTrials.govwebsite. Published June, Updated September Accessed March 7, Haukeland University Hospital. PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (PETREMAC). ClinicalTrials.gov website. Published November, Updated December Accessed March 7, Hospital General Universitario Gregorio Marañon. Predictors of Response to Neoadjuvant Docetaxel- Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer. ClinicalTrials.gov Web site. Published March, Updated February Accessed March 7, CMS National Coverage Determination (NCDs): No NCDs identified as of the writing of this policy. Local Coverage Determinations (LCDs): No LCDs identified as of the writing of this policy. Commonly submitted codes Below are the most commonly submitted codes for the service(s)/item(s) subject to this policy. This is not an exhaustive list of codes. Providers are expected to consult the appropriate coding manuals and bill in accordance with those manuals. 8
9 CPT Codes Description Comparative analysis using short tandem repeat markers: patient and comparative specimen Unlisted molecular pathology procedure (MammaPrint) Oncology (breast), mrna, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin embedded tissue, algorithm reported as recurrence score (Oncotype Dx) ICD-10 Code Description C Malignant neoplasm of nipple and areola, right female breast C Malignant neoplasm of nipple and areola, left female breast C Malignant neoplasm of nipple and areola, unspecified female breast C Malignant neoplasm of nipple and areola, right male breast C Malignant neoplasm of nipple and areola, left male breast C Malignant neoplasm of nipple and areola, unspecified male breast C Malignant neoplasm of central portion of right female breast C Malignant neoplasm of central portion of left female breast C Malignant neoplasm of central portion of unspecified female breast C Malignant neoplasm of central portion of right male breast C Malignant neoplasm of central portion of left male breast C Malignant neoplasm of central portion of unspecified male breast C Malignant neoplasm of upper-inner quadrant of right female breast C Malignant neoplasm of upper-inner quadrant of left female breast C Malignant neoplasm of upper-inner quadrant of unspecified female breast C Malignant neoplasm of upper-inner quadrant of right male breast C Malignant neoplasm of upper-inner quadrant of left male breast C Malignant neoplasm of upper-inner quadrant of unspecified male breast C Malignant neoplasm of lower-inner quadrant of right female breast C Malignant neoplasm of lower-inner quadrant of left female breast C Malignant neoplasm of lower-inner quadrant of unspecified female breast C Malignant neoplasm of lower-inner quadrant of right male breast C Malignant neoplasm of lower-inner quadrant of left male breast C Malignant neoplasm of lower-inner quadrant of unspecified male breast C Malignant neoplasm of upper-outer quadrant of right female breast C Malignant neoplasm of upper-outer quadrant of left female breast C Malignant neoplasm of upper-outer quadrant of unspecified female breast C Malignant neoplasm of upper-outer quadrant of right male breast C Malignant neoplasm of upper-outer quadrant of left male breast C Malignant neoplasm of upper-outer quadrant of unspecified male breast C Malignant neoplasm of lower-outer quadrant of right female breast C Malignant neoplasm of lower-outer quadrant of left female breast C Malignant neoplasm of lower-outer quadrant of unspecified female breast C Malignant neoplasm of lower-outer quadrant of right male breast C Malignant neoplasm of lower-outer quadrant of left male breast C Malignant neoplasm of lower-outer quadrant of unspecified male breast C Malignant neoplasm of axillary tail of right female breast C Malignant neoplasm of axillary tail of left female breast C Malignant neoplasm of axillary tail of unspecified female breast C Malignant neoplasm of axillary tail of right male breast C Malignant neoplasm of axillary tail of left male breast C Malignant neoplasm of axillary tail of unspecified male breast C Malignant neoplasm of overlapping sites of right female breast C Malignant neoplasm of overlapping sites of left female breast C Malignant neoplasm of overlapping sites of unspecified female breast C Malignant neoplasm of overlapping sites of right male breast C Malignant neoplasm of overlapping sites of left male breast 9
10 C Malignant neoplasm of overlapping sites of unspecified male breast C Malignant neoplasm of unspecified site of right female breast C Malignant neoplasm of unspecified site of left female breast C Malignant neoplasm of unspecified site of unspecified female breast C Malignant neoplasm of unspecified site of right male breast C Malignant neoplasm of unspecified site of left male breast C Malignant neoplasm of unspecified site of unspecified male breast HCPCS Codes N/A Description 10
Clinical Policy Title: Gene expression profile testing for breast cancer
Clinical Policy Title: Gene expression profile testing for breast cancer Clinical Policy Number: 02.01.14 Effective Date: December 1, 2013 Initial Review Date: July 17, 2013 Most Recent Review Date: February
More informationLocal Coverage Determination (LCD): MolDX: Breast Cancer Assay: Prosigna (L36125)
Local Coverage Determination (LCD): MolDX: Breast Cancer Assay: Prosigna (L36125) Contractor Information Contractor Name Palmetto GBA LCD Information Document Information LCD ID L36125 Original ICD-9 LCD
More informationBreast Cancer Recurrence Assay (MammaPrint )
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationDescription of Procedure or Service. assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer 11/2004 3/2015 3/2016 3/2015
Corporate Medical Policy Assays of Genetic Expression to Determine Prognosis of Breast File Name: Origination: Last CAP Review: Next CAP Review: Last Review: assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer
More informationHow To Use A Breast Cancer Test To Help You Choose Chemotherapy
Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat Issued: September
More informationOne of the most mature trials that examined PROCEEDINGS. Hormone Therapy in Postmenopausal Women With Breast Cancer * William J.
Hormone Therapy in Postmenopausal Women With Breast Cancer * William J. Gradishar, MD ABSTRACT *Based on a presentation given by Dr Gradishar at a roundtable symposium held in Baltimore on June 28, 25.
More informationClinical Policy Title: Leiomyosarcoma and Laparoscopic Power Morcellation
Clinical Policy Title: Leiomyosarcoma and Laparoscopic Power Morcellation Clinical Policy Number: 12.03.01 Effective Date: January 1, 2015 Initial Review Date: August 20, 2014 Most Recent Review Date:
More informationHAVE YOU BEEN NEWLY DIAGNOSED with DCIS?
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women
More informationAccelerated Partial Breast Irradiation (APBI) for Breast Cancer [Preauthorization Required]
Accelerated Partial Breast Irradiation (APBI) for Breast Cancer [Preauthorization Required] Medical Policy: MP-SU-01-11 Original Effective Date: February 24, 2011 Reviewed: Revised: This policy applies
More informationBreast Cancer Educational Program. June 5-6, 2015
Breast Cancer Educational Program June 5-6, 2015 Adjuvant Systemic Therapy For Early Breast Cancer: Who, What and for How Long? Debjani Grenier MD, FRCPC Medical Oncologist Disclosures Advisory Board Member:
More informationEffects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
More informationChemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationGuideline Development The American Society of Clinical Oncology
Assessing Genomic Sequencing Information for Health Care Decision Making Decision Making Once Evidence is Assessed/Graded Evaluated Guideline Development The American Society of Clinical Oncology Gary
More informationImpact of Gene Expression Profiling Tests on Breast Cancer Outcomes
Evidence Report/Technology Assessment Number 160 Impact of Gene Expression Profiling Tests on Breast Cancer Outcomes Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and
More informationAdjuvant Therapy for Breast Cancer: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Adjuvant Therapy for Breast
More informationAccelerated Partial Breast Irradiation (APBI) for Breast Cancer
Accelerated Partial Breast Irradiation (APBI) for Breast Cancer [For the list of services and procedures that need preauthorization, please refer to www.mcs.pr Go to Comunicados a Proveedores, and click
More informationPrognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
More informationBreast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationBreast Cancer. The Pathology report gives an outline on direction of treatment. It tells multiple stories to help us understand the patient s cancer.
Breast Cancer What Does the Pathology Report Say Normal Cells The Pathology report gives an outline on direction of treatment. It tells multiple stories to help us understand the patient s cancer. Non-Invasive
More informationBREAST CANCER PATHOLOGY
BREAST CANCER PATHOLOGY FACT SHEET Version 4, Aug 2013 This fact sheet was produced by Breast Cancer Network Australia with input from The Royal College of Pathologists of Australasia I m a nurse and know
More informationCellular, Molecular, and Biochemical Targets in Breast Cancer
Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm
More informationPatient Guide to Breast Cancer Surgery and Treatment
Patient Guide to Breast Cancer Surgery and Treatment Coree H. Flight attendant and mother of 3. Diagnosed with invasive breast cancer in 2009. An educational guide prepared by Genomic Health This Is Your
More informationAccelerated Partial Breast Irradiation (APBI) for Breast Cancer [Pre-authorization Required]
Accelerated Partial Breast Irradiation (APBI) for Breast Cancer [Pre-authorization Required] Medical Policy: MP-SU-01-11 Original Effective Date: February 24, 2011 Reviewed: February 24, 2012 Revised:
More informationSUBJECT: MANAGEMENT OF BREAST EFFECTIVE DATE: 12/16/99 IMPLANTS REVISED DATE:
MEDICAL POLICY SUBJECT: MANAGEMENT OF BREAST PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationPathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
More informationClinical Policy Title: Home uterine activity monitoring
Clinical Policy Title: Home uterine activity monitoring Clinical Policy Number: 12.01.01 Effective Date: August 19, 2015 Initial Review Date: July 17, 2013 Most Recent Review Date: July 15, 2015 Next Review
More informationPrognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee
Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee Breast cancer is the most common malignant tumor in American women and is second only to lung cancer as a
More informationSTATE OF MICHIGAN DEPARTMENT OF INSURANCE AND FINANCIAL SERVICES Before the Director of Insurance and Financial Services
STATE OF MICHIGAN DEPARTMENT OF INSURANCE AND FINANCIAL SERVICES Before the Director of Insurance and Financial Services In the matter of: Petitioner, v Blue Care Network of Michigan, Respondent. File
More informationNational Medical Policy
National Medical Policy Subject: Policy Number: Oncotype DX for Cancer NMP479 Effective Date*: January 2005 Updated: October 2015 This National Medical Policy is subject to the terms in the IMPORTANT NOTICE
More informationBreast Cancer. Abstract. Keywords. Development of the 21-gene Assay Oncotype DX
Evolution of the 21-gene Assay Oncotype DX from an Experimental Assay to an Instrument Assisting in Risk Prediction and Optimisation of Treatment Decision-making in Early Breast Cancer Christian Jackisch,
More informationRecommendations for the management of early breast cancer
Recommendations for the management of early breast cancer in women with an identified BRCA1 or BRCA2 gene mutation or at high risk of a gene mutation FEBRUARY 2014 Incorporates published evidence to August
More informationAppendix One. HER2-positive early breast cancer, its treatment and prognosis
Appendix One. HER2-positive early breast cancer, its treatment and prognosis Breast cancer and HER2/neu over-expression Health need is one of PHARMAC s nine decision criteria (http://www.pharmac.govt.nz/pdf/231205.pdf
More informationHER2 Testing in Breast Cancer
HER2 Testing in Breast Cancer GAIL H. VANCE, M.D. AGT MEETING JUNE 13, 2014 LOUISVILLE, KENTUCKY No Conflict of Interest to Report Human Epidermal Growth Factor Receptor 2-HER2 Human epidermal growth factor
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationBreast Cancer Treatment Guidelines
Breast Cancer Treatment Guidelines DCIS Stage 0 TisN0M0 Tamoxifen for 5 years for patients with ER positive tumors treated with: -Breast conservative therapy (lumpectomy) and radiation therapy -Excision
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationCMS Limitations Guide Mammograms and Bone Density Radiology Services
CMS Limitations Guide Mammograms and Bone Density Radiology Services Starting July 1, 2008, CMS has placed numerous medical necessity limits on tests and procedures. This reference guide provides you with
More informationICD-10 Diagnostic Coding for. Breast Reconstruction
ICD-10 Diagnostic Coding for Webinar Hosted by: Breast Reconstruction December 5, 2013 Presented by: Kim Pollock, RN, MBA, CPC Meet Kim Pollock RN, MBA, CPC Kim Pollock, RN, MBA, CPCspecializes in streamlining
More informationAdjuvant Endocrine Therapy in Breast Cancer: 2015 Update
Adjuvant Endocrine Therapy in Breast Cancer: 2015 Update Shannon Puhalla, MD Director, Breast Cancer Clinical Research Program Magee Womens Cancer Program University of Pittsburgh Cancer Institute Questions
More informationPositività per HER-2 nei carcinomi subcentimetrici
Positività per HER-2 nei carcinomi Antonella Ferro U.O. Oncologia Medica Trento Small Tumors Small tumors are becoming increasingly common with the use of mammography > screening Some of these tumors,
More informationEffect of Chemotherapy for Luminal A Breast Cancer
Yonago Acta medica 2013;56:51 56 Original Article Effect of Chemotherapy for Luminal A Breast Cancer Naotaka Uchida,* Takako Suda and Kiyosuke Ishiguro *Clinic of Surgery, Tottori Prefectural Kosei Hospital,
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationNancy E. Davidson, MD Johns Hopkins University. Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationBreast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis?
Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis? Erin I. Lewis, BUSM 2010 Cheri Nguyen, BUSM 2008 Priscilla Slanetz, M.D., MPH Al Ozonoff, Ph.d.
More informationMedical Policy Original Effective Date: 11-19-08 Revised Date: 1-27-16 Page 1 of 8
Page 1 of 8 Disclaimer Description Coverage Determination Refer to the member s specific benefit plan and Schedule of Benefits to determine coverage. This may not be a benefit on all plans, or the plan
More informationYour Guide to the Breast Cancer Pathology Report
Your Guide to the Breast Cancer Pathology Report Developed for you by Breastcancer.org is a nonprofit organization dedicated to providing education and information on breast health and breast cancer. The
More informationLocal Coverage Determination (LCD): MolDX: Genomic Health Oncotype DX Prostate Cancer Assay (L36153)
Local Coverage Determination (LCD): MolDX: Genomic Health Oncotype DX Prostate Cancer Assay (L36153) Contractor Information Contractor Name Palmetto GBA LCD Information Document Information LCD ID L36153
More informationAIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY
AIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY THE HERMARK BREAST CANCER ASSAY HERmark is based on our proprietary VeraTag technology that precisely quantifies HER2 proteins and protein complexes
More informationChanges in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
More informationHereditary Multifocal Breast Cancer. Farin Amersi M.D., F.A.C.S Division of Surgical Oncology Department of Surgery Cedar Sinai Medical Center
Hereditary Multifocal Breast Cancer Farin Amersi M.D., F.A.C.S Division of Surgical Oncology Department of Surgery Cedar Sinai Medical Center CASE STUDY 30 year old Ashkenazi Jewish woman Nulliparous Felt
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationMEDICAL POLICY EFFECTIVE DATE: 07/20/06 REVISED DATE: 10/18/07, 10/23/08, 10/29/09, 10/28/10, 03/17/11, 02/16/12, 01/17/13, 01/16/14
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationPersonalized Predictive Medicine and Genomic Clinical Trials
Personalized Predictive Medicine and Genomic Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://brb.nci.nih.gov brb.nci.nih.gov Powerpoint presentations
More informationBreakthrough Treatment Options for Breast Cancer
Breakthrough Treatment Options for Breast Cancer Guest Expert: Lyndsay, MD Associate Professor of Medical Oncology, Yale Cancer Center www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center
More informationAccess to hormone receptor testing and other basic diagnostic pathology services in Colombia
Access to hormone receptor testing and other basic diagnostic pathology services in Colombia Dr Fernando Perry Clínica de seno y tejidos blandos Instituto Nacional de Cancerología de Colombia Breast cancer
More informationClinical Policy Title: Air Ambulance Transport
Clinical Policy Title: Air Ambulance Transport Clinical Policy Number: 18.02.02 Effective Date: Sept. 1, 2014 Initial Review Date: April 16, 2014 Most Recent Review Date: May 21, 2014 Next Review Date:
More informationUnderstanding your pathology report
Understanding your pathology report 2 Contents Contents Introduction 3 What is a pathology report? 3 Waiting for your results 4 What s in a pathology report? 4 Information about your breast cancer 5 What
More informationSECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR.
SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR. TRACEY O CONNOR RESEARCH QUESTON Patients with previously diagnosed hematologic
More informationCorporate Medical Policy
Corporate Medical Policy Proteomics-based Testing Related to Ovarian Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteomics_based_testing_related_to_ovarian_cancer 7/2010
More informationDigital Health: Catapulting Personalised Medicine Forward STRATIFIED MEDICINE
Digital Health: Catapulting Personalised Medicine Forward STRATIFIED MEDICINE CRUK Stratified Medicine Initiative Somatic mutation testing for prediction of treatment response in patients with solid tumours:
More informationGene Expression Profiling in Breast Cancer
Molecular assays can assist in choosing therapy and predicting outcomes in almost 50% of women with breast cancer. Nick Patten. Martha (detail). Oil on panel, 22" 28". Gene Expression Profiling in Breast
More informationProportion of patients with invasive breast cancer in whom ER, PR and/or
1.1.a. Proportion of patients with invasive breast cancer in whom ER, PR and/or HER2 status assessment were performed 1.1.b. Proportion of patients with invasive breast cancer in whom systemic treatment
More informationMedicare Coverage of Genomic Testing
Medicare Coverage of Genomic Testing Louis B. Jacques, MD Director, DID/CAG/OCSQ With acknowledgements to Jeff Roche, MD Social Security Act 1862(a)(1)(A) Notwithstanding any other provision of this title,
More informationAbstract Introduction. Aim of the study. Conclusion. Patients and methods. Keywords. Results. R. Abo El Hassan 1, M. Moneer 2
Original Study Outcome of HER2 positive luminal operable breast cancer in comparison with outcome of other operable luminal breast cancer patients: Long follow-up of single center randomized study R. Abo
More informationYour Guide to the Breast Cancer Pathology Report
Your Guide to the Breast Cancer Pathology Report Developed for you by Breastcancer.org is a nonprofit organization dedicated to providing education and information on breast health and breast cancer. The
More informationCarcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology
Carcinoma of the Cervix Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Treatment Treatment Microinvasive (Stage IA1): Simple (extrafascial) hysterectomy/cone
More informationProgress and Prospects in Ovarian Cancer Screening and Prevention
Progress and Prospects in Ovarian Cancer Screening and Prevention Rebecca Stone, MD MS Assistant Professor Kelly Gynecologic Oncology Service The Johns Hopkins Hospital 1 No Disclosures 4/12/2016 2 Ovarian
More informationClinical Policy Title: Air Ambulance Transport
Clinical Policy Title: Air Ambulance Transport Clinical Policy Number: 18.02.02 Effective Date: Oct. 1, 2014 Initial Review Date: April 16, 2014 Most Recent Review Date: May 21, 2014 Next Review Date:
More informationPROVIDER POLICIES & PROCEDURES
PROVIDER POLICIES & PROCEDURES BRCA GENETIC TESTING The purpose of this document is to provide guidance to providers enrolled in the Connecticut Medical Assistance Program (CMAP) on the requirements for
More informationEpidemiology. Breast Cancer Screening, Diagnosis, Biology and Long-Term Follow-Up EDUCATIONAL OBJECTIVES
Cancer Treatment Centers of America Breast Cancer: Screening, Diagnosis, Biology and Long-Term Follow-Up Presented to: Atlantic Regional Osteopathic Conference Presented by: Pamela Crilley, DO Date: April
More informationHow To Determine If A Fall Prevention Program Is Effective
Clinical Policy Title: Medical alert devices and other interventions for vulnerable peoples safety at home Clinical Policy Number: 17.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21,
More informationMale breast cancer - Wikipedia, the free encyclopedia
pagina 1 van 5 Male breast cancer From Wikipedia, the free encyclopedia Male breast cancer is a relatively rare cancer in men that originates from the breast. As it presents a similar pathology as female
More information2015 HCPCS CODE ADDITIONS
2015 HCPCS CODE ADDITIONS Bolded Codes Bolded codes indicate notation of special billing policy. Chemotherapy A9606, C9442, J9267, J9301 A9606 Billing is for males only. C9442 Belinostat is used for the
More informationMetastatic Breast Cancer...
DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a
More informationElectronic health records to study population health: opportunities and challenges
Electronic health records to study population health: opportunities and challenges Caroline A. Thompson, PhD, MPH Assistant Professor of Epidemiology San Diego State University Caroline.Thompson@mail.sdsu.edu
More informationGenomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More informationwww.downstatesurgery.org
Male Breast Cancer Rabih Nemr MD Kings County Hospital August 2008 ACGME Core Competencies 1 Patient t Care Medical Knowledge 2 g 3 4 Practice Based Learning/Improvement Interpersonal Communication Skills
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationGuide to Understanding Breast Cancer
An estimated 220,000 women in the United States are diagnosed with breast cancer each year, and one in eight will be diagnosed during their lifetime. While breast cancer is a serious disease, most patients
More informationIs it time for a new drug development paradigm?
Is it time for a new drug development paradigm? Robert McDonough, M.D. Senior Director, Clinical Policy Research and Development 1 The Aetna Way Our Cause To make quality health care more affordable and
More informationOpportunities and Challenges in Translating Novel Discoveries into Useful Clinical Tests
Opportunities and Challenges in Translating Novel Discoveries into Useful Clinical Tests James H. Doroshow, M.D. NCI Deputy Director for Clinical and Translational Research NCI Workshop: Evidence Needed
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationChapter 2 Staging of Breast Cancer
Chapter 2 Staging of Breast Cancer Zeynep Ozsaran and Senem Demirci Alanyalı 2.1 Introduction Five decades ago, Denoix et al. proposed classification system (tumor node metastasis [TNM]) based on the dissemination
More informationGoals and Objectives: Breast Cancer Service Department of Radiation Oncology
Goals and Objectives: Breast Cancer Service Department of Radiation Oncology The breast cancer service provides training in the diagnosis, management, treatment, and follow-up of breast malignancies, including
More informationPharmacogenetic Activities in SWOG Breast Cancer
Pharmacogenetic Activities in SWOG Breast Cancer Pharmacogenomics: Future Plans S8897 Adjuvant CMF vs. CAF/ no Treatment Ambrosone RO1: Other genes (TBCI approved, analyses ongoing) S0221 Adjuvant Dose
More informationPATHOLOGY. HercepTestTM. Product Information
PATHOLOGY HercepTestTM Product Information CLINICAL TRIALS HercepTest The First and Foremost Dako s pharmdx HercepTest was the first FDA-approved assay developed exclusively to aid physicians in identifying
More informationDescription of Procedure or Service. gene_based_tests_for_screening_detection_or_management_of_prostate_cancer 4/2009 8/2015 8/2016 8/2015
Corporate Medical Policy Gene-Based Tests for Screening, Detection, and/or Management File Name: Origination: Last CAP Review: Next CAP Review: Last Review: gene_based_tests_for_screening_detection_or_management_of_prostate_cancer
More informationCorporate Medical Policy Brachytherapy Treatment of Breast Cancer
Corporate Medical Policy Brachytherapy Treatment of Breast Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: brachytherapy_treatment_of_breast_cancer 7/1996 5/2015 5/2016 5/2015
More informationProtein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
More informationGenetic Testing for Susceptibility to Breast and Ovarian Cancer (BRCA1 and BRCA 2)
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. M issouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationNational Coverage Determination (NCD) for Tumor Antigen by Immunoassay - CA 125 (190.28)
National Coverage Determination (NCD) for Tumor Antigen by Immunoassay - CA 125 (190.28) Tracking Information Publication Number Manual Section Number 100-3 190.28 Manual Section Title Tumor Antigen by
More informationBreast Implants and Reconstruction
Last Review Date: October 9, 2015 Number: MG.MM.SU.fv2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationBreast Cancer. CSC Cancer Experience Registry Member, breast cancer
ESSENTIALS Breast Cancer Take things one step at a time. Try not to be overwhelmed by the tidal wave of technical information coming your way. Finally you know your body best; you have to be your own advocate.
More informationFlorida Breast Health Specialists Breast Cancer Information and Facts
Definition Breast cancer is a cancer that starts in the tissues of the breast. There are two main types of breast cancer: Ductal carcinoma starts in the tubes (ducts) that move milk from the breast to
More informationUse of Oncotype DX for guiding adjuvant chemotherapy decisions in early stage invasive breast cancer patients in Alberta
Use of Oncotype DX for guiding adjuvant chemotherapy decisions in early stage invasive breast cancer patients in Alberta A Health Technology Assessment Simrandeep K Tiwana, Alison Smith, Laura Leggett,
More information